Renal Cell Carcinoma (RCC) Clinical Roundup

News Articles

(UC News) Oct 21, 2020 - Research shows tobacco use changes metabolism of kidney cancer, may lead to targeted treatments.
(BMS) Oct 19, 2020 - Bristol Myers Squibb and Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and supplemental New Drug Application (sNDA), respectively, for OPDIVO® (nivolumab) in combination with CABOMETYX® (cabozantinib) for patients...
(Regulatory Focus) Oct 1, 2020 - Two new draft guidances from the US Food and Drug Administration give investigators a roadmap for clinical trials of adjuvant drug or biologic therapy for two common cancers. The first of the guidances released on 1 October addresses adjuvant treatment for bladder cancer, and the other addresses...
(Medscape Medical News) Sept 25, 2020 - Patients with higher intraoperative blood loss and those treated at lower-volume surgical centers had a greater risk of high-grade complications after undergoing CN for mRCC, according data analysis.
View all renal cell carcinomca (rcc) cancer news


Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate 9ER and other I-O studies as they pertain to the management of RCC patients

Clinical Briefs

In the phase 3 CheckMate-9ER trial of patients with advanced renal cell carcinoma (aRCC), first-line treatment with nivolumab plus cabozantinib demonstrated superior progression-free survival (PFS), overall survival (OS), and objective response rates (ORR) compared with sunitinib.

Featured Kidney (Renal Cell Carcinoma) Cancer Tweets

Brian Rini, MD
brian_rini - Oct 26  @tompowles1, @ERPlimackMD and others update the KEYNOTE426 trial here:

Toni Choueri, MD
DrChoueiri - Oct 25  Fascinating work on ACE/ARB axis impact on IO-treated patients from @gulleyj1 group @theNCI building in prior repor…

Tian Zhang, MD, MHS
TiansterZhang - Oct 25  Keynote 426 pembro-axitinib publishes 30 month follow up data. Congratulations @tompowles1 @ERPlimackMD @brian_rini